

Referencias

1. Carroll MF, Burge MR, Schade DS. Severe hypoglycemia in adults. *Rev Endocr Metab Disord*. 2003;4(2):149-57.
2. Guettier JM, Gorden P. Hypoglycemia. *Endocrinol Metab Clin North Am*. 2006;35(4):753-66.
3. Hart SP, Frier BM. Causes, management and morbidity of acute hypoglycaemia in adults requiring hospital admission. *QJM*. 1998;91(7):505-10.
4. Huic M, Mucolic V, Vrhovac B, Francetic I, Bakran I, Giljanovic S. Adverse drug reactions resulting in hospital admission. *Int J Clin Pharmacol Ther*. 1994;32(12):675-82.
5. Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. *Diabetes*. 1997;46(2):271-86.
6. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. *Diabetes*. 1995;44(11):1249-58.
7. Hepburn DA, MacLeod KM, Pell AC, Scougal IJ, Frier BM. Frequency and symptoms of hypoglycaemia experienced by patients with type 2 diabetes treated with insulin. *Diabet Med*. 1993;10(3):231-7.
8. Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, Service FJ; Endocrine Society. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2009;94(3):709-28.
9. Dagogo-Jack SE, Craft S, Cryer PE. Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. *J Clin Invest*. 1993 Mar;91(3):819-28.
10. Cranston I, Lomas J, Maran A, Macdonald I, Amiel SA. Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. *Lancet*. 1994;344(8918):283-7.
11. Wahren J, Ekberg K, Fernqvist-Forbes E, Nair S. Brain substrate utilisation during acute hypoglycaemia. *Diabetologia*. 1999;42(7):812-8.

12. Gerich J, Cryer P, Rizza R. Hormonal mechanisms in acute glucose counterregulation: the relative roles of glucagon, epinephrine, norepinephrine, growth hormone, and cortisol. *Metabolism*. 1980;29(11 Suppl 1):1164-75.
13. Grunberger G, Weiner JL, Silverman R, Taylor S, Gorden P. Factitious hypoglycemia due to surreptitious administration of insulin. Diagnosis, treatment, and long-term follow-up. *Ann Intern Med*. 1988;108(2):252-7.
14. Gill G, Huda B, Boyd A, Skagen K, Wile D, Watson I, van Heyningen C. Characteristics and mortality of severe hyponatraemia—a hospital-based study. *Clin Endocrinol (Oxf)*. 2006;65(2):246-9.
15. Owen JA, Campbell DG. A comparison of plasma electrolyte and urea values in healthy persons and in hospital patients. *Clin Chim Acta*. 1968;22(4):611-8.
16. DeVita MV, Gardenswartz MH, Konecky A, Zabetakis PM. Incidence and etiology of hyponatremia in an intensive care unit. *Clin Nephrol*. 1990;34(4):163-6.
17. Zilberberg MD, Exuzides A, Spalding J, Foreman A, Jones AG, Colby C, Shorr AF. Epidemiology, clinical and economic outcomes of admission hyponatremia among hospitalized patients. *Curr Med Res Opin*. 2008;24(6):1601-8.
18. Hsu YJ, Chiu JS, Lu KC, Chau T, Lin SH. Biochemical and etiological characteristics of acute hyponatremia in the emergency department. *J Emerg Med*. 2005;29(4):369-74.
19. Burton D. Rose, Theodore W. Post. Trastornos de los electrolitos y del equilibrio ácido-base. 5Th Ed. The McGraw-Hill Companies, Inc. 2002. 697-745.
20. Robertson GL. Antidiuretic hormone. Normal and disordered function. *Endocrinol Metab Clin North Am*. 2001;30(3):671-94.
21. Goh KP. Management of hyponatremia. *Am Fam Physician*. 2004;69(10):2387-94.
22. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. *N Engl J Med*. 2007;356(20):2064-72.
23. Cerdà-Esteve M, Cuadrado-Godia E, Chillaron JJ, Pont-Sunyer C, Cucurella G, Fernández M, Goday A, Cano-Pérez JF, Rodríguez-Campello A, Roquer J. Cerebral salt wasting syndrome: review. *Eur J Intern Med*. 2008;19(4):249-54.
24. Rabinstein AA, Wijdicks EF. Hyponatremia in critically ill neurological patients. *Neurologist*. 2003;9(6):290-300.

25. Verbalis JG. Adaptation to acute and chronic hyponatremia: implications for symptomatology, diagnosis, and therapy. *Semin Nephrol.* 1998;18(1):3-19.
26. Mulloy AL, Caruana RJ. Hyponatremic emergencies. *Med Clin North Am.* 1995;79(1):155-68.
27. Laurenro R, Karp BI. Myelinolysis after correction of hyponatremia. *Ann Intern Med.* 1997;126(1):57-62.
28. Hillier TA, Abbott RD, Barrett EJ. Hyponatremia: evaluating the correction factor for hyperglycemia. *Am J Med.* 1999;106(4):399-403.
29. Vaidya C, Ho W, Freda BJ. Management of hyponatremia: providing treatment and avoiding harm. *Cleve Clin J Med.* 2010;77(10):715-26.
30. Freda BJ, Davidson MB, Hall PM. Evaluation of hyponatremia: a little physiology goes a long way. *Cleve Clin J Med.* 2004;71(8):639-50.
31. Chung HM, Kluge R, Schrier RW, Anderson RJ. Clinical assessment of extracellular fluid volume in hyponatremia. *Am J Med.* 1987;83(5):905-8.
32. Hoorn EJ, Zietse R. Hyponatremia revisited: translating physiology to practice. *Nephron Physiol.* 2008;108(3):p46-59.
33. Damaraju SC, Rajshekhar V, Chandy MJ. Validation study of a central venous pressure-based protocol for the management of neurosurgical patients with hyponatremia and natriuresis. *Neurosurgery.* 1997;40(2):312-6.
34. Ayus JC, Krothapalli RK, Arief AI. Treatment of symptomatic hyponatremia and its relation to brain damage. A prospective study. *N Engl J Med.* 1987;317(19):1190-5.
35. Lauriat SM, Berl T. The hyponatremic patient: practical focus on therapy. *J Am Soc Nephrol.* 1997;8(10):1599-607.
36. Sterns RH, Cappuccio JD, Silver SM, Cohen EP. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. *J Am Soc Nephrol.* 1994;4(8):1522-30.
37. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. *Am J Med.* 2007;120(11 Suppl 1):S1-21.
38. Adrogue HJ, Madias NE. Hyponatremia. *N Engl J Med.* 2000;342(21):1581-9.

39. Janicic N, Verbalis JG. Evaluation and management of hypo-osmolality in hospitalized patients. *Endocrinol Metab Clin North Am.* 2003;32(2):459-81.
40. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. *Lancet.* 2008;371(9624):1624-32.
41. Schrier RW, Gross P, Gheorghide M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. *N Engl J Med.* 2006;355(20):2099-112.
42. Ghali JK, Zmily HD, Farah JO, Daifallah S. Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia. *IDrugs.* 2010;13(11):782-92.
43. Villabona C. [Vasopressin receptor antagonists: the vaptans]. [Article in Spanish]. *Endocrinol Nutr.* 2010;57 Suppl 2:41-52.
44. Becker, K. Principles and Practice of Endocrinology and Metabolism. In: Lippincott Williams y Wilkins, third edition; 2001: 291.
45. Palevsky PM, Bhagrath R, Greenberg A. Hyponatremia in hospitalized patients. *Ann Intern Med.* 1996;124(2):197-203.
46. Adrogué HJ, Madias NE. Hyponatremia. *N Engl J Med.* 2000;342(20):1493-9.
47. Molina, P. Fisiología Endocrina. En: Serie Lange de Fisiología McGraw Hill. Segunda edición 2008; 37-43 y 262-266.
48. Robertson GL, Aycinena P, Zerbe RL. Neurogenic disorders of osmoregulation. *Am J Med.* 1982;72(2):339-53.
49. Nguyen MK, Kurtz I. Analysis of current formulas used for treatment of the dysnatremias. *Clin Exp Nephrol.* 2004;8(1):12-6.
50. Adrogué HJ, Madias NE. Aiding fluid prescription for the dysnatremias. *Intensive Care Med.* 1997;23(3):309-16.
51. Palevsky PM, Singer I. Hyponatremia. In: Glasscock RJ, ed. Current Therapy in Nephrology and Hypertension. 3rd ed. St. Louis: Mosby-Year Book; 1992.
52. Arieff A and Difronzo R. Fluid, electrolyte and acid-base disorders. In: second edition. Churchill livingstone; 1995.
53. Youn JH, McDonough AA. Recent advances in understanding integrative control of potassium homeostasis. *Annu Rev Physiol.* 2009;71:381-401.
54. Shih-Hua Lin. A Practical and Pathophysiologic Approach to Hypokalemia. *Hong Kong J Nephrol.* 2008;10(1):14-26.

55. Greenlee M, Wingo CS, McDonough AA, Youn JH, Kone BC. Narrative review: evolving concepts in potassium homeostasis and hypokalemia. *Ann Intern Med.* 2009;150(9):619-25.
56. Schaefer TJ, Wolford RW. Disorders of potassium. *Emerg Med Clin North Am.* 2005;23(3):723-47.
57. Clausen T. $\text{Na}^+\text{-K}^+$ pump regulation and skeletal muscle contractility. *Physiol Rev.* 2003;83(4):1269-324.
58. Cohn JN, Kowey PR, Whelton PK, Prisant LM. New guidelines for potassium replacement in clinical practice: a contemporary review by the National Council on Potassium in Clinical Practice. *Arch Intern Med.* 2000;160(16):2429-36.
59. Unwin RJ, Luft FC, Shirley DG. Pathophysiology and management of hypokalemia: a clinical perspective. *Nat Rev Nephrol.* 2011;7(2):75-84.
60. Clausen T. Hormonal and pharmacological modification of plasma potassium homeostasis. *Fundam Clin Pharmacol.* 2010;24(5):595-605.
61. Palmer BF. A physiologic-based approach to the evaluation of a patient with hypokalemia. *Am J Kidney Dis.* 2010;56(6):1184-90.
62. Elliott MJ, Ronksley PE, Clase CM, Ahmed SB, Hemmelgarn BR. Management of patients with acute hyperkalemia. *CMAJ.* 2010;182(15):1631-5.
63. Favus MJ, Goltzman D. Regulation of Calcium and Magnesium. Chapter 21. En: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. © 2008 American Society for Bone and Mineral Research. Published Online: 23 Dec 2009.
64. Body JJ, Bouillon R. Emergencies of calcium homeostasis. *Rev Endocr Metab Disord.* 2003;4(2):167-75.
65. Shane, E, Dinaz, I. Hypercalcemia: Pathogenesis, clinical manifestations, differential diagnosis, and management. In: Favus, MJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. Sixth ed. Philadelphia: Lippincott, Williams, and Wilkins. 2006; 26:176.
66. Lafferty FW. Differential diagnosis of hypercalcemia. *J Bone Miner Res.* 1991;6 Suppl 2:S51-9.
67. Wisneski LA. Salmon calcitonin in the acute management of hypercalcemia. *Calcif Tissue Int.* 1990;46 Suppl:S26-30.
68. Berenson JR. Treatment of hypercalcemia of malignancy with bisphosphonates. *Semin Oncol.* 2002;29(6 Suppl 21):12-8.

69. Shoback D. Clinical practice. Hypoparathyroidism. *N Engl J Med*. 2008;359(4):391-403.
70. Nayak B, Burman K. Thyrotoxicosis and thyroid storm. *Endocrinol Metab Clin North Am*. 2006;35(4):663-86.
71. Nayak B, Hodak SP. Hyperthyroidism. *Endocrinol Metab Clin North Am*. 2007;36(3):617-56.
72. Wartofsky L., Thyrotoxic Storm. En Werner-Ingbar. The Thyroid. A fundamental and clinical text. Eight Ed, Lippincott Williams & Wilkins Philadelphia 2000; 679-684.
73. Wartofsky L, Myxedema Coma. E, En Werner-Ingbar. The Thyroid. A fundamental and clinical text. Eight Ed, Lippincott Williams & Wilkins Philadelphia 2000; 843-847.
74. Gardner D., Greenspan F., Urgencias endocrinas. En Greenspan – Gardner Endocrinología Básica y Clínica Sexta Ed 2005 pags 929-932.
75. Fliers E, Wiersinga WM. Myxedema coma. *Rev Endocr Metab Disord*. 2003 May;4(2):137-41.
76. Iglesias P, Gomez-Pan A, Diez JJ. Coma mixedematoso. *Rev Clin Esp*. 1999;5:50-59.
77. Devdhar M, Ousman YH, Burman KD. Hypothyroidism. *Endocrinol Metab Clin North Am*. 2007;36(3):595-615.
78. Wartofsky L. Myxedema coma. *Endocrinol Metab Clin North Am*. 2006;35(4):687-98.
79. Means J.H., The Thyroid and its diseases, Ed J.B.Lippincott 2nd Ed, 1948 pags 202-267
80. Hall J, Schmidt G, Wood L. Acute Adrenal Insufficiency. In Principles of Critical Care Medicine 3Th Ed. 2005: 1219-1230. Copyright © 2005 by The McGraw-Hill Companies, Inc. ISBN: 0-07-141640-4
81. Gannon TA, Britt RC, Weireter LJ, Cole FJ, Collins JN, Britt LD. Adrenal insufficiency in the critically ill trauma population. *Am Surg*. 2006;72(5):373-6.
82. Annane D, Maxime V, Ibrahim F, Alvarez JC, Abe E, Boudou P. Diagnosis of adrenal insufficiency in severe sepsis and septic shock. *Am J Respir Crit Care Med*. 2006;174(12):1319-26.
83. Marik PE, Pastores SM, Annane D, Meduri GU, Sprung CL, Arlt W, Keh D, Briegel J, Beishuizen A, Dimopoulou I, Tsgarakis S, Singer M, Chrousos GP, Zaloga G, Bokhari F, Vogeser M; American College of Critical Care Medicine. Recommendations for

the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. *Crit Care Med*. 2008;36(6):1937-49.

84. Annane D, Sébille V, Troché G, Raphaël JC, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. *JAMA*. 2000;283(8):1038-45.
85. Opper M, Schindler R, Husung C, Offermann K, Gräf KJ, Boenisch O, Barckow D, Frei U, Eckardt KU. Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. *Crit Care Med*. 2005;33(11):2457-64.
86. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre PF, Reinhart K, Cuthbertson BH, Payen D, Briegel J; CORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. *N Engl J Med*. 2008;358(2):111-24.